NewcelX Ltd. (NCEL)

NewcelX Ltd. (NCEL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $16.5M; returns 1 day +3.9%, 1 week +6.4%.

NewcelX Ltd. (NCEL) is a Swiss clinical-stage biopharmaceutical company focused on developing transformative cell-based and small-molecule therapies for severe neurodegenerative and metabolic diseases. The company was formed in October 2025 through the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., consolidating expertise in advanced stem-cell technologies and neuroscience.

Groups NCEL belongs to

• Biotechnology
• Biopharmaceutical
• Recent Reverse Splits
• Clinical Stage Biotech
• Neuroscience
• Neurological Disorders
• Metabolic Disorders
• CNS Disorders
• Type 1 Diabetes
• Clinical Stage
• Regenerative Medicine
• Healthcare

NCEL financial model: income statement, cash flow and balance sheet